Assessing ImmunityBio (IBRX) Valuation After Trial Progress And Strong Anktiva Commercial Momentum [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
Why ImmunityBio's latest bladder cancer trial update matters for the stock ImmunityBio (IBRX) has attracted fresh attention after reporting that its Phase 2 QUILT 2.005 trial in BCG naïve non muscle invasive bladder cancer completed enrollment ahead of schedule. Interim data showed statistically significant response durability for ANKTIVA plus BCG compared with BCG alone. See our latest analysis for ImmunityBio. The trial update lands on top of a sharp share price move, with ImmunityBio's 30 day share price return of 60.50% and year to date share price return of 372.77% reflecting strong momentum. The 1 year total shareholder return of 233.92% points to sizeable recent gains as Anktiva approvals, partnerships across Europe and the Middle East, and better than expected 2025 earnings have come through. If progress at ImmunityBio has you rethinking where growth in cancer and immunotherapy could come from next, it might be worth scanning our screener of 29 healthcare AI stocks as
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 [Yahoo! Finance]Yahoo! Finance
- ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026Business Wire
- Is It Too Late To Consider ImmunityBio (IBRX) After The Recent Share Price Surge? [Yahoo! Finance]Yahoo! Finance
- SHINE Raises $240 Million in Funding to Advance Commercial Fusion Technology [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 2/26/26 - Form 4
- 2/25/26 - Form SCHEDULE
- 2/24/26 - Form 4
- IBRX's page on the SEC website